|
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
HER2 over-expression was detected in 23 out of 49 (46.9%) patients with intestinal GC, and 9 out of 35 (25.7%) patients with diffuse GC.
|
22654433 |
2012 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
|
29530054 |
2018 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Trastuzumab in combination with chemotherapy is the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive breast and gastric cancers.
|
28223426 |
2017 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Notably, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric cancer, and has become the standard-of-care treatment for this group of patients.
|
31548601 |
2020 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Using anti-HER2/neu antibody and the proposed HER2/neu scoring system for gastric cancer, HER2/neu IHC expression was recorded after manual scoring and automated IA interpretation.
|
22646266 |
2012 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Combination of trastuzumab with cytotoxic chemotherapy has demonstrated a survival advantage in patients with Her2/Neu positive gastric cancer.
|
23288635 |
2013 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
This experiment investigated the suppressive role of miR-3622b-5p in ERBB2-positive breast and gastric cancers.
|
28160563 |
2017 |
|
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Altogether, NCI-N87 cell line constitutes an appealing in vitro model to address glycan-mediated regulation of ErbB2 in GC.
|
29143776 |
2017 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Gene amplification and protein overexpression of the growth factor receptors c-erbB2 and K-sam may be prognostic factors for intestinal- and diffuse-type gastric cancer, respectively.
|
11525306 |
2000 |
|
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
HER2 overexpression/amplification is linked to trastuzumab response in breast/gastric cancers.
|
26690310 |
2016 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
HER2-ECD (human epidermal growth factor receptor 2 - extracellular domain) is a prominent therapeutic target validated for treating HER2-positive breast and gastric cancer, but HER2-specific therapeutic options for treating advanced gastric cancer remain limited.
|
30365359 |
2019 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, oxaliplatin-Au-Fe<sub>3</sub>O<sub>4</sub>-Herceptin is a promising multifunctional platform for simultaneous magnetic traceable and HER2 targeted chemotherapy for gastric cancer.
|
29731915 |
2018 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
GC patients (n = 237), including a subset from the Trastuzumab in GC (ToGA) trial were divided into three groups based on HER2 status and history of treatment with standard chemotherapy or chemotherapy plus trastuzumab.
|
27687309 |
2017 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Trastuzumab is currently used for patients with Her2(+) advanced gastric cancer.
|
23630346 |
2013 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
|
25611242 |
2015 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Unlike in breast and gastric cancer, currently there are no established guidelines for HER2 testing in endometrial carcinoma.
|
23765245 |
2013 |
|
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
HER2 overexpression is associated with metastasis-the main cause of death in individuals with gastric cancer.
|
20460098 |
2010 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).
|
24473399 |
2014 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative gastric cancer is a major challenge.
|
31423245 |
2019 |
|
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Since intratumoral HER2 heterogeneity is also an important issue, a multicenter large-scale study was conducted to evaluate the prognostic impacts of HER2 expression and intratumoral heterogeneity in gastric cancer.
|
25224659 |
2015 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The HER2 gene is known to play an important role in the oncogenesis of several types of cancers, such as breast, ovarian, colon and gastric cancers.
|
14618618 |
2004 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Aside from the human epidermal growth factor receptor-2 (HER2)-targeting agent trastuzumab, molecular targeting therapy for gastric cancer (GC) has not been established.
|
23110662 |
2012 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
|
31587095 |
2019 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The most relevant new agent in gastric cancer therapy is trastuzumab for HER2-positive gastric carcinomas.
|
21896085 |
2011 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
HER2/neu amplification is associated with response to HER2/neu-directed therapy in breast and gastric cancers.
|
26022204 |
2015 |